{"transactions":[{"id":693818,"issuer":{"id":4984,"kind":"organization","name":"Attovia Therapeutics, Inc.","symbol":"ATTO"},"owners":[{"id":25707,"kind":"organization","name":"Frazier Life Sciences XI, L.P.","position":1,"cik":"0001911592","reported_name":"Frazier Life Sciences XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25708,"kind":"organization","name":"FHMLS XI, L.P.","position":2,"cik":"0001911580","reported_name":"FHMLS XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25709,"kind":"organization","name":"FHMLS XI, L.L.C.","position":3,"cik":"0001911623","reported_name":"FHMLS XI, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2026-08-06T21:35:51.000Z","date":"2026-08-06","kind":"exercise","planned":false,"acquired":false,"shares":8930685,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of the IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of the IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of the IPO and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":961322},"source":{"system":"sec-edgar","filing":"0001231919-26-000838","document":"form4-08062026_090845.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1911592/000123191926000838/form4-08062026_090845.xml","form_type":"4"}},{"id":693817,"issuer":{"id":4984,"kind":"organization","name":"Attovia Therapeutics, Inc.","symbol":"ATTO"},"owners":[{"id":25707,"kind":"organization","name":"Frazier Life Sciences XI, L.P.","position":1,"cik":"0001911592","reported_name":"Frazier Life Sciences XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25708,"kind":"organization","name":"FHMLS XI, L.P.","position":2,"cik":"0001911580","reported_name":"FHMLS XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25709,"kind":"organization","name":"FHMLS XI, L.L.C.","position":3,"cik":"0001911623","reported_name":"FHMLS XI, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-08-06T21:35:51.000Z","date":"2026-08-06","kind":"exercise","planned":false,"acquired":false,"shares":11054544,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of the IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of the IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of the IPO and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1189940},"source":{"system":"sec-edgar","filing":"0001231919-26-000838","document":"form4-08062026_090845.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1911592/000123191926000838/form4-08062026_090845.xml","form_type":"4"}},{"id":693816,"issuer":{"id":4984,"kind":"organization","name":"Attovia Therapeutics, Inc.","symbol":"ATTO"},"owners":[{"id":25707,"kind":"organization","name":"Frazier Life Sciences XI, L.P.","position":1,"cik":"0001911592","reported_name":"Frazier Life Sciences XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25708,"kind":"organization","name":"FHMLS XI, L.P.","position":2,"cik":"0001911580","reported_name":"FHMLS XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25709,"kind":"organization","name":"FHMLS XI, L.L.C.","position":3,"cik":"0001911623","reported_name":"FHMLS XI, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Preferred Stock","published_at":"2026-08-06T21:35:51.000Z","date":"2026-08-06","kind":"exercise","planned":false,"acquired":false,"shares":14772727,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series A-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of the IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series A-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of the IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series A-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of the IPO and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1590175},"source":{"system":"sec-edgar","filing":"0001231919-26-000838","document":"form4-08062026_090845.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1911592/000123191926000838/form4-08062026_090845.xml","form_type":"4"}},{"id":693815,"issuer":{"id":4984,"kind":"organization","name":"Attovia Therapeutics, Inc.","symbol":"ATTO"},"owners":[{"id":25707,"kind":"organization","name":"Frazier Life Sciences XI, L.P.","position":1,"cik":"0001911592","reported_name":"Frazier Life Sciences XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25708,"kind":"organization","name":"FHMLS XI, L.P.","position":2,"cik":"0001911580","reported_name":"FHMLS XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25709,"kind":"organization","name":"FHMLS XI, L.L.C.","position":3,"cik":"0001911623","reported_name":"FHMLS XI, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2026-08-06T21:35:51.000Z","date":"2026-08-06","kind":"exercise","planned":false,"acquired":false,"shares":16250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of\nthe Issuer's initial public offering (the \"IPO\") and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of\nthe Issuer's initial public offering (the \"IPO\") and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of\nthe Issuer's initial public offering (the \"IPO\") and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1749192},"source":{"system":"sec-edgar","filing":"0001231919-26-000838","document":"form4-08062026_090845.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1911592/000123191926000838/form4-08062026_090845.xml","form_type":"4"}},{"id":693814,"issuer":{"id":4984,"kind":"organization","name":"Attovia Therapeutics, Inc.","symbol":"ATTO"},"owners":[{"id":25707,"kind":"organization","name":"Frazier Life Sciences XI, L.P.","position":1,"cik":"0001911592","reported_name":"Frazier Life Sciences XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25708,"kind":"organization","name":"FHMLS XI, L.P.","position":2,"cik":"0001911580","reported_name":"FHMLS XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25709,"kind":"organization","name":"FHMLS XI, L.L.C.","position":3,"cik":"0001911623","reported_name":"FHMLS XI, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-06T21:35:51.000Z","date":"2026-08-06","kind":"purchase","planned":false,"acquired":true,"shares":588235,"price":17,"value":9999995.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P."}],"balance_after":6154213,"source":{"system":"sec-edgar","filing":"0001231919-26-000838","document":"form4-08062026_090845.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1911592/000123191926000838/form4-08062026_090845.xml","form_type":"4"}},{"id":693813,"issuer":{"id":4984,"kind":"organization","name":"Attovia Therapeutics, Inc.","symbol":"ATTO"},"owners":[{"id":25707,"kind":"organization","name":"Frazier Life Sciences XI, L.P.","position":1,"cik":"0001911592","reported_name":"Frazier Life Sciences XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25708,"kind":"organization","name":"FHMLS XI, L.P.","position":2,"cik":"0001911580","reported_name":"FHMLS XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25709,"kind":"organization","name":"FHMLS XI, L.L.C.","position":3,"cik":"0001911623","reported_name":"FHMLS XI, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-06T21:35:51.000Z","date":"2026-08-06","kind":"exercise","planned":false,"acquired":true,"shares":961322,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of the IPO and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P."}],"balance_after":5565978,"source":{"system":"sec-edgar","filing":"0001231919-26-000838","document":"form4-08062026_090845.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1911592/000123191926000838/form4-08062026_090845.xml","form_type":"4"}},{"id":693812,"issuer":{"id":4984,"kind":"organization","name":"Attovia Therapeutics, Inc.","symbol":"ATTO"},"owners":[{"id":25707,"kind":"organization","name":"Frazier Life Sciences XI, L.P.","position":1,"cik":"0001911592","reported_name":"Frazier Life Sciences XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25708,"kind":"organization","name":"FHMLS XI, L.P.","position":2,"cik":"0001911580","reported_name":"FHMLS XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25709,"kind":"organization","name":"FHMLS XI, L.L.C.","position":3,"cik":"0001911623","reported_name":"FHMLS XI, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-06T21:35:51.000Z","date":"2026-08-06","kind":"exercise","planned":false,"acquired":true,"shares":1189940,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of the IPO and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P."}],"balance_after":4604656,"source":{"system":"sec-edgar","filing":"0001231919-26-000838","document":"form4-08062026_090845.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1911592/000123191926000838/form4-08062026_090845.xml","form_type":"4"}},{"id":693811,"issuer":{"id":4984,"kind":"organization","name":"Attovia Therapeutics, Inc.","symbol":"ATTO"},"owners":[{"id":25707,"kind":"organization","name":"Frazier Life Sciences XI, L.P.","position":1,"cik":"0001911592","reported_name":"Frazier Life Sciences XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25708,"kind":"organization","name":"FHMLS XI, L.P.","position":2,"cik":"0001911580","reported_name":"FHMLS XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25709,"kind":"organization","name":"FHMLS XI, L.L.C.","position":3,"cik":"0001911623","reported_name":"FHMLS XI, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-06T21:35:51.000Z","date":"2026-08-06","kind":"exercise","planned":false,"acquired":true,"shares":1590175,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series A-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of the IPO and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P."}],"balance_after":3414716,"source":{"system":"sec-edgar","filing":"0001231919-26-000838","document":"form4-08062026_090845.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1911592/000123191926000838/form4-08062026_090845.xml","form_type":"4"}},{"id":693810,"issuer":{"id":4984,"kind":"organization","name":"Attovia Therapeutics, Inc.","symbol":"ATTO"},"owners":[{"id":25707,"kind":"organization","name":"Frazier Life Sciences XI, L.P.","position":1,"cik":"0001911592","reported_name":"Frazier Life Sciences XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25708,"kind":"organization","name":"FHMLS XI, L.P.","position":2,"cik":"0001911580","reported_name":"FHMLS XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25709,"kind":"organization","name":"FHMLS XI, L.L.C.","position":3,"cik":"0001911623","reported_name":"FHMLS XI, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-06T21:35:51.000Z","date":"2026-08-06","kind":"exercise","planned":false,"acquired":true,"shares":1749192,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of\nthe Issuer's initial public offering (the \"IPO\") and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P."}],"balance_after":1824541,"source":{"system":"sec-edgar","filing":"0001231919-26-000838","document":"form4-08062026_090845.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1911592/000123191926000838/form4-08062026_090845.xml","form_type":"4"}}]}